Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07295847 · ClinicalTrials.gov registry record · Phase 1

A Study of AZD0120 in Autoimmune Diseases

A Phase 1 study of Rheumatoid Arthritis and Systemic Sclerosis, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
27
Enrollment target
18
Study locations

NCT07295847 is a Phase 1 study of Rheumatoid Arthritis and Systemic Sclerosis that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 27 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 18 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07295847, a Phase 1 study of Rheumatoid Arthritis and Systemic Sclerosis, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
27 participants
Enrollment target
18
Study locations

Study Summary

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).

Conditions Studied

Rheumatoid Arthritis Systemic Sclerosis Idiopathic Inflammatory Myopathies

Interventions

  • BIOLOGICAL AZD0120

Study Locations (18)

Other

  • Research Site - Darlinghurst
  • Research Site - Waratah
  • Research Site - Hamburg
  • Research Site - Mainz Am Rhein
  • Research Site - Würzburg
  • Research Site - Barcelona
  • Research Site - Madrid
  • Research Site - Madrid
  • Research Site - Edinburgh
  • Research Site - London

Arizona

  • Research Site - Tucson

California

  • Research Site - Stanford

Illinois

  • Research Site - Chicago

Michigan

  • Research Site - Ann Arbor

Missouri

  • Research Site - St Louis

New York

  • Research Site - New York

North Carolina

  • Research Site - Chapel Hill

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2026-01-09
Est. Completion 2028-02-22
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07295847

The ClinicalTrials.gov registry entry for NCT07295847 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which AZD0120 is the first listed.

NCT07295847 reports 18 study locations spanning 9 distinct geographic areas - top geographies include Other, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT07295847 about?

NCT07295847 is a clinical study titled "A Study of AZD0120 in Autoimmune Diseases". This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthr...

What is the current status of trial NCT07295847?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2026-01-09. Estimated completion is 2028-02-22.

What conditions does trial NCT07295847 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis, Systemic Sclerosis, Idiopathic Inflammatory Myopathies.

What interventions are being tested in trial NCT07295847?

The interventions under investigation include: AZD0120 (BIOLOGICAL).

Who is sponsoring clinical trial NCT07295847?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07295847 being conducted?

This trial has 18 study locations across Arizona, California, Illinois, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Systemic Sclerosis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.